European countries are undergoing rapid and substantial demographic and technological changes. Yet, healthcare systems are still mainly state-funded and acute-focused, as they have been for the past 70 years. This is starting to change.
Unilabs CEO and company doctor Jos Lamers is cock-a-hoop over second quarter sales growth of 7.1% at constant exchange rates and sees a trend towards the public sector outsourcing. Unilabs, the Pan-West European lab and imaging group, was a late entry in to the race to buy Pan-Euro lab group synlab this summer and Lamers is keen to make more acquistions. We talk to him about the results and how he sees the lab sector.
Although the regulation restricting private operators changed as far back as in 2000, private players have only started to play a role over the past two years. So why the sudden shift? Tom Tidemann, CEO of Unicare, says 11 years of socialist ‘red-green’ governments hindered the drive for a more commercial approach to healthcare. With a right-wing coalition in office, fair public-private competition can finally emerge.
Colosseum Smile Group CEO Per Rehnberg looks at how Colosseum, by far the largest Scandinavian dentist chain, is building its brand in terms of service quality, internal culture and marketing. Presented at the Healthcare Europa Annual Conference 2015, Creating the New Healthcare Services Landscape. Click here to view the presentation
Aleris, the Pan-Scandinavian hospital-to-elderly care group controlled by Investor has bought Teres, the pan-Scandinavian group which claims to be the largest elective surgery operator in the region. The move diversifies Aleris away from its dependence on Swedish public payors. We look at the deal in detail and talk to Teres CEO Ase Aulie Michelet.
Memira, the largest Scandinavian ophthalmology chain, backed by private equity house Investor Growth Capital, is now expanding operations into Finland. It had estimated 2014 sales of €60m. We talk to CEO Andreas Göthberg about growth trends, its business model, the importance of customer service and building a brand.
Listed investment company Gimv (Euronext: GIMB) is unusual in that it covers every aspect of health – biopharma, medtech and healthcare services – with a focus on mid-caps and a Pan-European approach. It is willing to invest as little as a few million euros up to € 50m and can hold a stake for up to 10-12 years. Active in biopharma since the early eighties, it has also made several investments in healthcare services and medical technologies. So how does Mr. Diels who has worked in VC and private equity for 20 years, view healthcare services as an investment perspective?
We talk to academics and policymakers about TTIP's potential impact on public sector healthcare provision in Europe. Fear, uncertainty and doubt surround the discussions between the European Union and the United States on the Transatlantic Trade & Investment Partnership (TTIP) and its possible impact on public healthcare services.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.